Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1284 participants.

Also called NCT02168829

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 1,284 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02168829
Other papers using this trial's data
  • Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation The New England journal of medicine, 2026-01-22 DOI, PubMed 41211931

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Australia, Belgium, Canada, China, Germany, Israel (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02168829. Randomized; no masking; primary purpose prevention. Start 2016-01 (actual); primary completion 2025-08-14 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial
Acronym
OCEAN
Condition
Stroke
Intervention (Drug)
Rivaroxaban
Intervention (Drug)
Acetylsalicylic acid
Lead sponsor
Ottawa Heart Institute Research Corporation (class: other)
Collaborator
Canadian Institutes of Health Research (CIHR) (class: other government)
Collaborator
Bayer (class: industry)
Collaborator
Biotronik Canada Inc (class: industry)
Collaborator
Abbott (class: industry)

Record details

Record id
cardio:ct-nct02168829
Content hash
7d410ba96a40f71c0c537c13c946368f7790033b5036e934d9ff47d0a2e58927